Clinical characteristics and biomarkers of severe immune checkpoint inhibitor-related pneumonitis triggered by immunotherapy followed by radiation: a case report

Clinical characteristics and biomarkers of severe immune checkpoint inhibitor-related pneumonitis triggered by immunotherapy followed by radiation: a case report

BackgroundThe advent of immune checkpoint inhibitors (ICIs) has revolutionized the treatment landscape for tumor patients, dramatically improving survival rate. However, patients treated with immunotherapy are inevitably at risk of immune-related adverse events (irAEs). Immune checkpoint inhibitor-r...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yan Zhu, Jianhe Yu, Qun Ren, Xiang Wu, Hongxia Xu, Tian Tian, Jiang Liu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-11-01
Series:	Frontiers in Immunology
Subjects:	pneumonitis immunotherapy immune checkpoint inhibitors (ICIs) immune-related adverse event (irAE) immune checkpoint inhibitor-related pneumonitis (ICI-P) biomarkers
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1454114/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Endocrine Adverse Events in Patients Treated with Immune Checkpoint Inhibitors: A Comprehensive Analysis
by: Meriç Dökmetaş, et al.
Published: (2025-01-01)

Immune checkpoint inhibitor-related pneumonitis following discontinuation of pembrolizumab in a patient with advanced lung adenocarcinoma: a case report and literature review
by: Huan Wang, et al.
Published: (2024-12-01)

Immune-related adverse events with renal colic as the main manifestation: a case report of sintilimab-induced ureteritis/cystitis treated by ureteral stent and review of the literature
by: Jiaxiang Ji, et al.
Published: (2024-12-01)

Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland
by: Ichiro Yamauchi, et al.
Published: (2023-10-01)

Clinical characteristics and potential biomarkers of thyroid and pituitary immune-related adverse events
by: Tomoko Kobayashi, et al.
Published: (2024-01-01)

CD73/adenosine dynamics in treatment-induced pneumonitis: balancing efficacy with risks of adverse events in combined radio-immunotherapies
by: Lena Gockeln, et al.
Published: (2025-01-01)

The impact of immune-related adverse events on the outcome of advanced gastric cancer patients with immune checkpoint inhibitor treatment
by: Tianhang Zhang, et al.
Published: (2024-12-01)

Immune checkpoint inhibitors-related thyroid dysfunction: influencing factor analysis, prediction model development, and management strategy proposal
by: Xinya Li, et al.
Published: (2024-11-01)

Revisiting immune checkpoint inhibitors: new strategies to enhance efficacy and reduce toxicity
by: Dianying Zhang, et al.
Published: (2024-12-01)

Emerging Ocular Side Effects of Immune Checkpoint Inhibitors: A Comprehensive Review
by: Kevin Y. Wu, et al.
Published: (2024-11-01)

Sex-Related Differences in Immunotherapy Outcomes of Patients with Advanced Non-Small Cell Lung Cancer
by: Sara Frida Cohen, et al.
Published: (2024-11-01)

Cyclosporine successfully treats steroid-resistant checkpoint inhibitor-related pneumonitis: a case report
by: Jiaxi Deng, et al.
Published: (2024-11-01)

Safety and efficacy of immune checkpoint inhibitors in patients with pre-treatment reduced left ventricular function
by: Maor Tzuberi, et al.
Published: (2025-01-01)

Correlation between thyroid dysfunction and efficacy of immune checkpoint inhibitors in patients with advanced solid tumors
by: Cheng Zhao
Published: (2024-11-01)

A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance
by: Ginette S. Santiago-Sánchez, et al.
Published: (2024-12-01)

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
by: Ichiro Yamauchi, et al.
Published: (2025-01-01)

Immune-related thyroid dysfunction as a positive prognostic factor for patients with lung cancer in China: a real-world retrospective study
by: Ge Guo, et al.
Published: (2024-12-01)

Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
by: Jing Wei, et al.
Published: (2024-12-01)

Pembrolizumab Induced Recall Dermatitis Occurring 5 Years After Radiotherapy
by: Caroline J. Cushman, et al.
Published: (2024-11-01)

Immune Checkpoints in B Cells: Unlocking New Potentials in Cancer Treatment
by: Xiaoye Shi, et al.
Published: (2024-12-01)

Fluorescence Lifetime Imaging of NAD(P)H in Patients’ Lymphocytes: Evaluation of Efficacy of Immunotherapy
by: Diana V. Yuzhakova, et al.
Published: (2025-01-01)

Tissue-resident memory T cells in immune-related adverse events: friend or foe?
by: Robin Reschke, et al.
Published: (2023-12-01)

Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives
by: Yuhang Chen, et al.
Published: (2024-12-01)

The safety and efficacy of immune checkpoint blockade in children, adolescents, and young adults: A systematic review and meta-analysis
by: Pedro C.A. Reis, et al.
Published: (2025-06-01)

Immune checkpoint inhibitor-induced diabetes mellitus: clinical characteristics and risk factors
by: Mei Zhan, et al.
Published: (2025-01-01)

Establishment of an animal model of immune‐related adverse events induced by immune checkpoint inhibitors
by: Yuan Meng, et al.
Published: (2024-07-01)

Identifying subgroups deriving the most benefit from PD-1 checkpoint inhibition plus chemotherapy in advanced metastatic triple-negative breast cancer: a systematic review and meta-analysis
by: Shengfa Lin, et al.
Published: (2024-12-01)

Antiviral therapy can effectively suppress irAEs in HBV positive hepatocellular carcinoma treated with ICIs: validation based on multi machine learning
by: Shuxian Pan, et al.
Published: (2025-01-01)

Immune Checkpoint Inhibitors and Vaccination: Assessing Safety, Efficacy, and Synergistic Potential
by: Jacob New, et al.
Published: (2024-11-01)

Impact of steroid-sparing immunosuppressive agents on tumor outcome in the context of cancer immunotherapy with highlight on melanoma: a systematic literature review and meta-analysis
by: Jennifer Strouse, et al.
Published: (2024-12-01)

Efficacy of high-dose steroids versus low-dose steroids in the treatment of immune checkpoint inhibitor-associated myocarditis: a case series and systematic review
by: Xiuyue Man, et al.
Published: (2025-02-01)

Acute kidney injury in patients treated with immune checkpoint inhibitors: a single-center retrospective study
by: Ping Zhou, et al.
Published: (2024-12-01)

Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report
by: Camille M. Powers, et al.
Published: (2024-12-01)

Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations
by: Benjamin C. Park, et al.
Published: (2023-12-01)

Association between smoking status, toxicity and survival in the checkpoint inhibitor immunotherapy
by: Anna Rudzińska, et al.
Published: (2024-11-01)

Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)
by: A Daban, et al.
Published: (2023-12-01)

Cytokine release syndrome after treatment with immune checkpoint inhibitors: an observational cohort study of 2672 patients from Karolinska University Hospital in Sweden
by: Osama Hamida, et al.
Published: (2024-12-01)

Characterising immune-related adverse events in different types of cancer among Chinese patients receiving immune checkpoint inhibitors
by: Qi Zhang, et al.
Published: (2024-12-01)

Risk of immune‐related pneumonitis for PD1/PD‐L1 inhibitors: Systematic review and network meta‐analysis
by: Yafang Huang, et al.
Published: (2019-05-01)

Alopecia and hair repigmentation associated with anti-programmed death-ligand 1 (PD-L1) immunotherapy
by: Jennifer Strong, BS, et al.
Published: (2025-02-01)